Lipid profile pattern in pediatric overweight population with or without NAFLD in relation to IDF criteria for metabolic syndrome: a preliminary study

Balanescu, A.; Bălănescu, Paul; Comanici, Valentina Daniela; Stan, Iustina Violeta; Acs, Beata; Prisăcariu, Laura; Brezan, Florin; Ciomârtan, Tatiana; Gherghina, I

doi:10.1515/rjim-2017-0040

Cited by 7 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with previous studies (103), Balanescu et al (104) have recently documented that NAFLD patients presented a very high TG/HDL-C ratio and a tendency to hyperuricemia and lower HDL levels compared with non-NAFLD patients.…”

Section: Common Pathogenetic Mechanisms Linking Nafld and Metssupporting

confidence: 91%

The Liver in Children With Metabolic Syndrome

2019

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is recognized as an emerging health risk in obese children and adolescents. NAFLD represents a wide spectrum of liver conditions, ranging from asymptomatic steatosis to steatohepatitis. The growing prevalence of fatty liver disease in children is associated with an increased risk of metabolic and cardiovascular complications. NAFLD is considered the hepatic manifestation of Metabolic Syndrome (MetS) and several lines of evidence have reported that children with NAFLD present one or more features of MetS. The pathogenetic mechanisms explaining the interrelationships between fatty liver disease and MetS are not clearly understood. Altough central obesity and insulin resistance seem to represent the core of the pathophysiology in both diseases, genetic susceptibility and enviromental triggers are emerging as crucial components promoting the development of NAFLD and MetS in children. In the present review we have identified and summarizied studies discussing current pathogenetic data of the association between NAFLD and MetS in children.

show abstract

Section: Common Pathogenetic Mechanisms Linking Nafld and Metssupporting

confidence: 91%

The Liver in Children With Metabolic Syndrome

2019

View full text Add to dashboard Cite

show abstract

“…Anthropometric assessment results and patients' characteristics are described in Tables 1 and 2, respectively. Study population characteristics were also fully described in a previously published study based on the MR-PONy cohort [12,13].…”

Section: Resultsmentioning

confidence: 99%

“…We conducted a cross-sectional study on 68 consecutive pediatric patients admitted in a single center (Pediatric Clinic of the National Institute for Mother and Child Health "Alessandrescu-Rusescu," Bucharest) in a one-year period (January to December 2017). Those patients were part of the MR-PONy cohort (Metabolic and cardiovascular Risk factors in a Pediatric Overweight and obese population with or without NAFLD) whose characteristics were previously fully described in our previous studies [12,13]. All eligible patients had not been treated prior to enrollment.…”

Section: Methodsmentioning

confidence: 99%

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Balanescu

Codreanu

Comanici

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

The aim of the study was to evaluate serum Endocan and Lumican levels as biomarkers for pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and to explore their associations with pediatric cardiometabolic risk factors. We conducted a cross-sectional study on 68 pediatric obese and overweight (O&O) patients. Ten healthy controls were recruited. Serum Lumican and Endocan levels were analyzed using ELISA kits. O&O patients had lower levels of Endocan compared to healthy controls (p<0.001). There were no differences between serum Endocan levels in O&O patients with NAFLD and those without (p=0.53). Patients considered having Nonalcoholic Steatohepatitis (NASH) had lower Endocan levels compared to O&O patients without NASH (p=0.026). Patients with metabolic syndrome had lower levels of Endocan (p=0.003). There were no significant differences between serum Lumican levels in O&O children compared to healthy controls. Lumican levels were higher in patients with hypertension (p=0.04). In O&O patients, Lumican levels were negatively correlated with Endocan levels (r=−0.37, p=0.002). Endocan seems a promising biomarker for the evaluation of pediatric NASH. Lumican was not confirmed as a biomarker for NAFLD in our cohort but was associated with higher arterial pressure. Low Endocan levels are accompanied by high serum Lumican levels, and this could be an early signature of cardiometabolic risk.

show abstract

“…Patients under the age of ten with both MS and NAFLD met the triglyceride criterion more frequently. This study showed that triglyceride levels are associated with NAFLD independently [28].These would be beneficial in order to detect possible NAFLD or MS at younger age and even if IDF Consensus Criteria are still not yet met, a close follow-up of these patients is mandatory. Bjorklund et al showed the association between the development of NAFLD and the occurrence of MS. Children having liver steatosis and elevated liver enzymes are most often asymptomatic [29].…”

Section: Discussionmentioning

confidence: 78%

Usefulness of the metabolic syndrome diagnosis in obese children in clinical practice

Springwald

Różana-Kowalska

Gibala

et al. 2019

pedm

View full text Add to dashboard Cite

Introduction: In the light of recent studies, the usefulness of the metabolic syndrome diagnosis in obese pediatric patients seems to be controversial. It leads to the pressing questions, if the metabolic syndrome diagnosis is reflecting risk of the cardiovascular complications in obese children. Aim of the study: To evaluate the incidence of metabolic syndrome in obese children, asses the role of insulin resistance in the metabolic complications and investigate if the diagnosis of MS has a clinical value in that group of patients. Material and methods: After the retrospective analysis of 588 records of obese children treated in metabolic outpatient clinic, 289 children (145 boys) in the mean age of 11 years, was qualified to the study. Diagnosis of metabolic syndrome was based on IDF 2009 criteria and HOMA-IR was used in the assessment of insulin resistance. Results: Metabolic syndrome was diagnosed in 69 children (24%) including 42 girls (61%, p < 0.05). Mean age was higher (12.4 vs. 10.9, p < 0.05) in patients with metabolic syndrome. Initial BMI Z-score was similar in the both groups (2.93 SD vs. 2.92 SD). However, further follow-up showed significantly (p < 0.001) less effective BMI z-score reduction in patients with metabolic syndrome. Insulin resistance was observed significantly more often in children with metabolic syndrome (77% vs. 35%, p < 0.0001). Moreover, aminotransferases were significantly higher in boys with metabolic syndrome (AST = 35 vs. 28 U/l, ALT = 38 vs. 23 U/l, p < 0.0001). Conclusions: The diagnosis of metabolic syndrome in obese children seems to have a predictive value for the clinical practice. Affected children are older and their criteria are present more often in girls. Insulin resistance seems to be an important factor associated with metabolic syndrome in obese children. The outcomes of behavioral therapy are less effective in children with metabolic syndrome. Affected boys are at higher risk of non-alcoholic fatty liver disease (NAFLD) in the future.

show abstract

Lipid profile pattern in pediatric overweight population with or without NAFLD in relation to IDF criteria for metabolic syndrome: a preliminary study

Cited by 7 publications

References 16 publications

The Liver in Children With Metabolic Syndrome

The Liver in Children With Metabolic Syndrome

Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Usefulness of the metabolic syndrome diagnosis in obese children in clinical practice

Contact Info

Product

Resources

About